Compare TIMKEN INDIA with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TIMKEN INDIA vs INDOCO REMEDIES - Comparison Results

TIMKEN INDIA     Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TIMKEN INDIA INDOCO REMEDIES TIMKEN INDIA/
INDOCO REMEDIES
 
P/E (TTM) x 37.4 70.3 53.2% View Chart
P/BV x 6.9 4.1 167.9% View Chart
Dividend Yield % 0.1 0.3 22.1%  

Financials

 TIMKEN INDIA   INDOCO REMEDIES
EQUITY SHARE DATA
    TIMKEN INDIA
Mar-19
INDOCO REMEDIES
Mar-18
TIMKEN INDIA/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs812317 255.8%   
Low Rs496178 278.4%   
Sales per share (Unadj.) Rs221.3113.1 195.7%  
Earnings per share (Unadj.) Rs19.84.5 442.5%  
Cash flow per share (Unadj.) Rs30.311.8 256.6%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.20.4 37.9%  
Book value per share (Unadj.) Rs178.373.2 243.4%  
Shares outstanding (eoy) m75.2092.15 81.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.02.2 134.8%   
Avg P/E ratio x33.155.5 59.6%  
P/CF ratio (eoy) x21.621.0 102.9%  
Price / Book Value ratio x3.73.4 108.4%  
Dividend payout %5.122.4 22.6%   
Avg Mkt Cap Rs m49,17722,830 215.4%   
No. of employees `0001.25.5 22.5%   
Total wages/salary Rs m1,2272,209 55.5%   
Avg. sales/employee Rs Th13,587.21,910.1 711.3%   
Avg. wages/employee Rs Th1,001.6405.0 247.3%   
Avg. net profit/employee Rs Th1,213.475.5 1,608.1%   
INCOME DATA
Net Sales Rs m16,64410,419 159.7%  
Other income Rs m16347 346.9%   
Total revenues Rs m16,80710,466 160.6%   
Gross profit Rs m2,8861,349 213.9%  
Depreciation Rs m793677 117.2%   
Interest Rs m18235 7.5%   
Profit before tax Rs m2,238484 462.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m75272 1,038.4%   
Profit after tax Rs m1,486412 361.1%  
Gross profit margin %17.312.9 133.9%  
Effective tax rate %33.615.0 224.5%   
Net profit margin %8.94.0 226.1%  
BALANCE SHEET DATA
Current assets Rs m8,7625,373 163.1%   
Current liabilities Rs m3,1034,157 74.7%   
Net working cap to sales %34.011.7 291.3%  
Current ratio x2.81.3 218.4%  
Inventory Days Days7068 102.6%  
Debtors Days Days6673 90.9%  
Net fixed assets Rs m5,0176,244 80.4%   
Share capital Rs m752184 408.1%   
"Free" reserves Rs m12,6556,566 192.8%   
Net worth Rs m13,4076,750 198.6%   
Long term debt Rs m01,233 0.0%   
Total assets Rs m17,75712,363 143.6%  
Interest coverage x128.23.1 4,190.4%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.90.8 111.2%   
Return on assets %8.55.2 161.9%  
Return on equity %11.16.1 181.8%  
Return on capital %16.89.0 186.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,9283,762 104.4%   
Fx outflow Rs m3,8151,143 333.7%   
Net fx Rs m1132,619 4.3%   
CASH FLOW
From Operations Rs m2,4881,227 202.7%  
From Investments Rs m-1,097-1,360 80.7%  
From Financial Activity Rs m-233-388 60.1%  
Net Cashflow Rs m1,195-521 -229.5%  

Share Holding

Indian Promoters % 0.0 59.2 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 5.5 12.5 44.0%  
FIIs % 6.4 6.0 106.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.2 22.4 58.9%  
Shareholders   49,890 12,805 389.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TIMKEN INDIA With:   COX & KINGS  IIFL FINANCE  GREENPLY INDUSTRIES  IL&FS INV. MANAGERS  CENTURY PLYBOARDS  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TIMKEN INDIA Announces Quarterly Results (2QFY20); Net Profit Up 44.1% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TIMKEN INDIA has posted a net profit of Rs 498 m (up 44.1% YoY). Sales on the other hand came in at Rs 4 bn (down 3.1% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

TIMKEN INDIA Announces Quarterly Results (1QFY20); Net Profit Up 59.6% (Quarterly Result Update)

Aug 16, 2019 | Updated on Aug 16, 2019

For the quarter ended June 2019, TIMKEN INDIA has posted a net profit of Rs 505 m (up 59.6% YoY). Sales on the other hand came in at Rs 4 bn (up 14.2% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TIMKEN INDIA SHARE PRICE


Apr 13, 2021 (Close)

TRACK TIMKEN INDIA

  • Track your investment in TIMKEN INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

TIMKEN INDIA 5-YR ANALYSIS

COMPARE TIMKEN INDIA WITH

MARKET STATS